Paper42469833
SPP1-positive macrophages drive trastuzumab resistance in HER2-positive breast cancer.
Wang D and 13 others. Cell Commun Signal, 2026. Cited by 1 paper, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Download JSON
Cite this record
ConductScience Library. SPP1-positive macrophages drive trastuzumab resistance in HER2-positive breast cancer. Papers, record 42469833. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42469833
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Trastuzumab | Major topic |
| Breast Neoplasms | Major topic |
| Erb-b2 Receptor Tyrosine Kinases | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Macrophages | Major topic |
| Humans | |
| Female | |
| Animals | |
| Tumor Microenvironment | |
| Killer Cells, Natural | |
| Mice | |
| Cell Line, Tumor |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| LHJJ2023-YX06 | the Joint Innovation Fund of Xijing Hospital Innovation Research Institute | PubMed | ||
| No. 2022JC-53 | Shaanxi Science Fund for Distinguished Young Scholars | PubMed | ||
| 82072910, 81902678, 82373894, 82304540, and 82172788 | National Natural Science Foundation of China | PubMed |
Source PubMed
References59
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33,268,821 | Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. | Nat Commun | 2020 | https://conductscience.org/library/papers/33268821 | PubMed |
| 2 | 26,842,237 | Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/26842237 | PubMed |
| 3 | 34,285,779 | UCell: Robust and scalable single-cell gene signature scoring. | Comput Struct Biotechnol J | 2021 | https://conductscience.org/library/papers/34285779 | PubMed |
| 4 | 26,606,967 | Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. | Sci Transl Med | 2015 | https://conductscience.org/library/papers/26606967 | PubMed |
| 5 | 39,066,845 | The resistance to anoikis, mediated by Spp1, and the evasion of immune surveillance facilitate the invasion and metastasis of hepatocellular carcinoma. | Apoptosis | 2024 | https://conductscience.org/library/papers/39066845 | PubMed |
| 6 | 34,914,499 | Pan-cancer single-cell landscape of tumor-infiltrating T cells. | Science | 2021 | https://conductscience.org/library/papers/34914499 | PubMed |
| 7 | 41,203,813 | TGF-β builds a dual immune barrier in colorectal cancer by impairing T cell recruitment and instructing immunosuppressive SPP1+ macrophages. | Nat Genet | 2025 | https://conductscience.org/library/papers/41203813 | PubMed |
| 8 | 38,715,072 | Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer. | Mol Cancer | 2024 | https://conductscience.org/library/papers/38715072 | PubMed |
| 9 | 39,934,144 | Lactate and lactylation in cancer. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/39934144 | PubMed |
| 10 | 31,178,118 | Comprehensive Integration of Single-Cell Data. | Cell | 2019 | https://conductscience.org/library/papers/31178118 | PubMed |
| 11 | 39,349,495 | SPP1+ macrophages in HR+ breast cancer are associated with tumor-infiltrating lymphocytes. | NPJ Breast Cancer | 2024 | https://conductscience.org/library/papers/39349495 | PubMed |
| 12 | 39,727,934 | SPP1 mRNA Expression Is Associated with M2 Macrophage Infiltration and Poor Prognosis in Triple-Negative Breast Cancer. | Curr Issues Mol Biol | 2024 | https://conductscience.org/library/papers/39727934 | PubMed |
| 13 | 34,650,042 | Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions. | Nat Commun | 2021 | https://conductscience.org/library/papers/34650042 | PubMed |
| 14 | 34,158,475 | Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab. | Signal Transduct Target Ther | 2021 | https://conductscience.org/library/papers/34158475 | PubMed |
| 15 | 41,310,768 | Senescent SPP1+ macrophages remodel the tumor microenvironment and promote the progression of early-stage lung adenocarcinoma featured with mixed ground glass nodule. | Mol Cancer | 2025 | https://conductscience.org/library/papers/41310768 | PubMed |
| 16 | 29,914,354 | Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. | BMC Genomics | 2018 | https://conductscience.org/library/papers/29914354 | PubMed |
| 17 | 40,021,788 | Emerging clinical applications of single-cell RNA sequencing in oncology. | Nat Rev Clin Oncol | 2025 | https://conductscience.org/library/papers/40021788 | PubMed |
| 18 | 25,035,397 | Osteopontin shapes immunosuppression in the metastatic niche. | Cancer Res | 2014 | https://conductscience.org/library/papers/25035397 | PubMed |
| 19 | 19,097,774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 20 | 30,867,590 | Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. | Nature | 2019 | https://conductscience.org/library/papers/30867590 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42,698,831 | Cyclin-dependent kinase 4 and 6 inhibitors and the breast cancer immune ecosystem: immune remodeling, resistance, and therapeutic reprogramming. | Front Immunol | 2026 | https://conductscience.org/library/papers/42698831 |
Source PubMed
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| ERBB2 | 2,064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| SPP1 | 6,696 | PubTator's text mining | https://conductscience.org/library/genes/6696 | NCBI Gene |
| TIGIT | 201,633 | PubTator's text mining | https://conductscience.org/library/genes/201633 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42469833
GET https://conductscience.org/api/papers/v1/42469833/references?page=2